How to build new logo pipeline for bioinformatics platforms sold to translational research teams

The translational lead owns a programme with a readout attached to it. An interim analysis, a filing, a go or no go decision, a data package that goes in front of an investor or a regulator. They are the buyer, because they are the only person whose problem is measured in months.

The computational biology lead, or at a small company the single bioinformatician, is both your champion and your most likely cause of death. This is the defining feature of the sale. They will be asked to evaluate a product that does some of what they do, in front of their own leadership, and no amount of feature quality fixes what that feels like if you handle it badly.

Then there is a governance layer that has no interest in your science at all. Privacy office, security review, data use agreements, and in a hospital an institutional review board that works to its own calendar. None of these people will ever say yes to you. All of them can say no, and at an academic centre they are usually the reason a decided deal takes another nine months.

Finally, the scientists who will actually use it, who never appear in the sales process and decide the renewal. They abandon software silently, and the first anyone notices is when usage reporting comes up at year end.

This audience is technical, sceptical and largely right about the things they believe. You do not move them by disagreeing. You move them by changing which question is being asked.

What they believe today.

• This is an analysis problem. The question is whether the right algorithm exists and whether we can run it, and the answer is usually yes, because the field publishes its methods.
• We already have a pipeline. Somebody built it, it works, it has been used on three studies, and it cost nothing beyond salary.
• Open source is free and excellent, which is true, and anything commercial has to beat free on capability before it is worth discussing.
• Buying software is an admission that our computational team is not fast enough.
• Our data cannot leave, so cloud products are largely irrelevant to us.

What has to be true before they can buy.

• The product is not the analysis, it is the defensibility of the analysis. The question that arrives in eighteen months is whether the result can be reproduced today with the same pipeline versions and an audit trail attached, and for most translational groups the honest answer is no. That is not a capability gap, it is an exposure, and it belongs to the programme lead rather than to the bioinformatician.
• The pipeline is not free, it is unpriced. Its cost is a fraction of one person's year, permanently, and it is paid in the months that person did not spend on biology. Ask what came off the queue to keep it running and the number becomes visible for the first time.
• The constraint is the queue, not the compute. Every translational group has one computational person who is the bottleneck for every programme in the building, and everyone can name the study that waited. Software that shortens that queue is leverage for that person rather than a replacement of them, and it has to be said in exactly those words.
• Open source and commercial are not competing answers to the same question. Nobody is selling against the algorithms. The thing being sold is version locking, provenance, reproducibility and somebody to call, which the open source project has never claimed to provide and does not want to.
• Deployment is a solved problem and should be raised by you first. Their environment, their cloud tenancy, their firewall. A vendor who volunteers the deployment answer before being asked has removed the objection that kills most of these deals silently.

The reframe in one move: stop selling better analysis to the person who does the analysis, and start selling reproducibility to the person who will have to defend the result. Those are two different people, two different problems and two different budgets.

• Trial registry entries listing correlative or biomarker endpoints. Public, dated, and they name the sponsor, the phase and the start date. A trial with a correlative arm means somebody has committed to producing an analysis nobody has staffed yet.
• Conference abstracts. Abstract books for the major oncology, genetics and translational meetings publish weeks ahead, are searchable, and name the presenting author, the assay, the cohort size and the institution. This is the single richest source in the niche and almost nobody works it systematically.
• The first computational hire at a small biotech. A post for a bioinformatics scientist or pipeline engineer says the analysis burden has outgrown the founding team, and a post that names specific frameworks tells you exactly what you would be sitting alongside.
• Financing rounds and regulatory filings at small biotechs. A financing puts a date on the next data package. A filing turns the translational data from an internal document into an external one.
• Publications and preprints with data availability and methods statements. Methods sections cite tool versions, which is the incumbent stack described by the buyer themselves, in public, with a date.
• Sequencing platform and instrument purchases, and core facility expansions. New data generation capacity creates an analysis problem within about a quarter, reliably.
• Consortium, biobank and data sharing announcements. These create multi site analysis problems that no single institution's pipeline was designed for, and the governance work is already underway when the announcement lands.

Conference abstracts and trial registry entries are the two to build on. Between them they tell you the assay, the cohort, the person and the date, which is more than most outbound programmes in any niche ever get.

• Is there a programme with a date? A readout, an interim analysis, a filing. Translational groups with no date behave exactly like discovery groups, which means they will evaluate you enthusiastically for a year and buy nothing.
• How many computational people are there, and is the answer between one and four? Zero means you are selling services and should price accordingly. More than about six usually means a build culture with an internal platform team, which is a much longer sale.
• Is the data human subject data, and does a governance path already exist? An institution that has executed data use agreements recently will do it again. One that has not is a nine month timeline wearing a three month disguise.
• Whose budget is it? A programme budget moves at the speed of the programme. A platform or informatics budget moves annually and usually in the autumn. Find out in the first conversation, because it sets everything else.

Write about their study, not your platform. This audience has a strong and instant filter for people who do not understand the assay, and one wrong sentence about the biology ends the thread permanently.

The abstract they presented six weeks ago is the best opening in the niche, because it is recent, specific, public and something they are proud of.

Notice that none of these mention a feature and all of them describe a failure mode the reader has either lived through or is about to. That is what earns the reply here.

• AI powered anything. This audience has been reading machine learning papers for a decade and treats the phrase as evidence that the sender has not.
• A sensitivity or accuracy claim without naming the reference set and the version. The first reply will ask which truth set, and if you do not have the answer in the original email you have already lost the technical evaluation.
• A demonstration on your demonstration data. It proves nothing to someone whose entire question is what happens on their cohort, with their batch effects and their missing metadata.
• Comparison tables against open source projects. Many of your readers have contributed to those projects, some maintain them, and an attack on the tool reads as an attack on the community.
• Anything that positions the software as a replacement for the computational team, including the polite versions. There is no polite version.

We already have a pipeline. Of course they do, and arguing with it is the fastest way out of the account. Ask one question instead: when did you last reproduce a result from two years ago, and how long did it take. The silence that follows is the sale. What they have is a working pipeline, which is not the same as a reproducible one, and the difference only matters on the day it matters enormously.

Our bioinformatician could build this. Almost certainly true, and say so plainly, then move to the cost. Ask what is currently in the queue, and what got pushed to make room for pipeline maintenance last quarter. The answer is always a study, and the programme lead in the room usually did not know it.

How do we know your calls are correct? The right answer is a concordance plan agreed in advance rather than a claim. Name the reference sets, agree the metrics, and commit to presenting the divergences yourself. Every pipeline disagrees with every other pipeline somewhere, and the vendor who surfaces that first is credible while the one who is caught by it is finished.

The data cannot leave our environment. Treat this as a specification rather than an objection, and get to it in the first conversation. If the answer is a deployment inside their tenancy, say so before they ask. If the answer is that you cannot, say that too, because discovering it in month four costs you the account and the reference.

• Landing engagement on a single study or programme: commonly $25K to $100K a year, scoped to one cohort with one named owner, and treated as the paid evaluation rather than a free pilot.
• Platform agreement for a translational group: commonly $100K to $400K a year, priced on studies, samples or seats depending on which one grows with their success rather than with your effort.
• Migration and method validation services attached to the first year: the work of moving an existing pipeline across and demonstrating concordance, priced separately so it does not disappear into the licence.
• Deployment inside the customer's environment: a premium and a support obligation, and the thing that decides whether hospital accounts are reachable for you at all.
• Signer: the chief scientific officer at a small biotech, an institute or department head at an academic centre, with governance able to delay indefinitely. Cycle: three to nine months commercial, nine to eighteen months academic, and renewal decided by end users who never attended a sales meeting.

The renewal point deserves attention, because it is where this niche differs from most software. You are sold by the programme lead and kept by the scientists, so usage reporting is not a reporting feature, it is your early warning system.

• Around each major meeting, work the abstract book the week it publishes. This is the highest yield fortnight in the year and it happens several times, so build the calendar around it.
• Weekly, pull new trial registrations with correlative or biomarker endpoints in your therapeutic areas, and note the sponsor size, because a small sponsor has no internal platform to fall back on.
• Weekly, pull computational and bioinformatics job posts at small biotechs, reading the named frameworks as the incumbent stack.
• Monthly, scan new publications and preprints in your assay space for methods statements, which give you the stack and the people together.
• Ten to fifteen accounts a week. Each first email needs the abstract or the trial read properly, because a wrong sentence about the assay is unrecoverable with this audience.
• Three touches, then stop. The next abstract, the next trial and the next hire are all coming, and each is a legitimate reason to reappear without repeating yourself.

Everyone in this market is selling better analysis to the person who already does the analysis. The opening is to sell reproducibility to the person who has to defend the result.

Everything above is about who and what. This is about how, and it is where most outbound in this niche quietly dies. Seven rules. None of them are optional.

None of this is specific to your niche. All of it is specific to whether anyone ever reads the angle you spent an hour getting right.

That is what we do. ExpertLayer runs this exact loop for firms with proprietary technology: the abstract book worked the week it publishes, the registry pull for correlative endpoints, the methods statements that reveal the incumbent stack, the hire that signals the tipping point, the angle written per account in the language of that assay, the sending across warmed mailboxes, and the reply reading. You take the scientific conversations, because nobody can have those for you.

The first step is free and it is the same research described above. Send us your website and we will come back with 10 companies that hit these triggers right now, with the abstract, the trial or the hire, the contact, and the opening line for each.